Latest news
Targeted Therapy Resistance in NSCLC: Critical Next Steps - OncodailyOncodaily · Sun, 09 Aug 2026 15:22:32 GMTBenjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape - The ASCO PostThe ASCO Post · Sun, 09 Aug 2026 02:02:31 GMTHER2 Mutations in NSCLC: Critical Risks of Outdated Terms - OncodailyOncodaily · Fri, 07 Aug 2026 16:43:17 GMTLCT Gains Ground in EGFR-Mutated NSCLC - OncLiveOncLive · Fri, 07 Aug 2026 14:05:45 GMTTreatment Strategies Following Progression in EGFR-Mutant NSCLC - OncLiveOncLive · Fri, 07 Aug 2026 01:41:15 GMTRisk Stratification and Treatment Selection in EGFR-Mutant NSCLC - OncLiveOncLive · Thu, 06 Aug 2026 19:45:26 GMTEGFR Amplification in EGFR-Mutated NSCLC: Critical Risk Marker - OncodailyOncodaily · Wed, 05 Aug 2026 14:17:49 GMTLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR NewswirePR Newswire · Mon, 03 Aug 2026 11:45:00 GMT